Last reviewed · How we verify

NCT06963541

IL-40 and IL-41 Levels in Sepsis, Septic Shock, and Healthy Individuals

Not yet recruiting Last updated 9 May 2025
What this trial tests

trial testing No intervention; Observational study in Sepsis in 80 participants. Not yet recruiting.

Timeline
15 May 2025
Primary endpoint
30 November 2025
31 December 2025

Quick facts

Lead sponsorMelahat Yalcin Solak
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment80
Start date15 May 2025
Primary completion30 November 2025
Estimated completion31 December 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Melahat Yalcin Solak

Who can join

18 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the blood levels of two recently identified immune-related proteins, Interleukin-40 (IL-40) and Interleukin-41 (IL-41), in patients with sepsis and its more severe form, septic shock. Sepsis is a serious condition caused by an abnormal immune response to infection, which can lead to organ dysfunction. Septic shock represents an advanced stage of sepsis, characterized by significantly higher mortality risk. IL-40 and IL-41 are newly discovered molecules that are thought to play important roles in the immune system. In this study, the blood concentrations of IL-40 and IL-41 in patients diagnosed with sepsis or septic shock will be measured and compared with those in healthy individuals. The findings may contribute to understanding whether these proteins can be used as biomarkers in the diagnosis or monitoring of treatment in sepsis-related conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention; Observational study

Trials testing the same drug.

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06963541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing